- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00103792
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis
The purpose of this study is to determine the efficacy and safety of a new drug, mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis). Therefore, we compare the standard therapy with cyclophosphamide to mycophenolate mofetil.
The investigators expect mycophenolate mofetil to be less toxic and almost equally effective as cyclophosphamide.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment of ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic drugs, and, secondly, after remission is achieved, maintenance therapy with less toxic drugs. The standard induction therapy of a relapse of Wegener's granulomatosis or microscopic polyangiitis consists of the combination of cyclophosphamide and prednisolone. Although this induction therapy is very effective, it is very toxic as well.
Searching for an alternative for cyclophosphamide, we will test the efficacy and safety of a new combination therapy with mycophenolate mofetil and prednisolone. We will compare the effect and safety of the standard induction therapy with the new therapy. When relapses occur, patients will be randomized for either the standard therapy with cyclophosphamide or for mycophenolate mofetil.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Patricia M. Stassen, M.D., Ph.D.
- Phone Number: +31433876543
- Email: p.stassen@mumc.nl
Study Contact Backup
- Name: Coen A. Stegeman, M.D., Ph.D.
- Phone Number: +31503616161
- Email: c.a.stegeman@int.umcg.nl
Study Locations
-
-
-
Groningen, Netherlands, 9700 RB
- Recruiting
- University Medical Centre Groningen
-
Contact:
- Patricia Stassen, M.D.
- Phone Number: +31503611295
- Email: p.m.stassen@int.umcg.nl
-
Contact:
- Coen Stegeman, M.D., Ph. D.
- Phone Number: +31503616161
- Email: c.a.stegeman@int.umcg.nl
-
Sub-Investigator:
- Patricia Stassen, M.D. pH.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- First or second relapse ANCA-associated vasculitis
- PR3- or MPO-ANCA antibodies present or histological proof of relapse
- Adult
Exclusion Criteria:
- Severe alveolar bleeding or (imminent) respiratory failure
- Renal failure (serum creatinine >500 umol/L or dialysis)
- Maintenance therapy before start of study consisting of: cyclophosphamide > 100 mg/day or prednisolone >25 mg/day
- Intolerance or allergy for cyclophosphamide, mycophenolate mofetil or azathioprine
- Gravidity or inadequate anticonception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
|
2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
|
Active Comparator: 2
cyclophosphamide
|
2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
remission induction rate
Time Frame: 6 months
|
6 months
|
disease free survival after 2 and 4 years
Time Frame: 2 and 4 years
|
2 and 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
time to remission
Time Frame: 9 months
|
9 months
|
cumulative organ damage
Time Frame: 4 years
|
4 years
|
side-effects
Time Frame: 4 years
|
4 years
|
ANCA titres over time
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Coen Stegeman, MD PhD, UMCG Groningen
Publications and helpful links
General Publications
- Stegeman CA; Cohen Tervaert JW. Mycophenolate mofetil for remission induction in patients with active Wegener's Granulomatosis (WG) intolerant for cyclophosphamide. J Am Soc Nephrol(11):98A, 2000
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Cerebral Small Vessel Diseases
- Systemic Vasculitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Vasculitis
- Granulomatosis with Polyangiitis
- Microscopic Polyangiitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cyclophosphamide
- Mycophenolic Acid
Other Study ID Numbers
- WG-MMF-1
- UMCG-ANCA-MMF-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital, BrestRecruiting
-
Nantes University HospitalINSERM UMRS-1064CompletedANCA-associated VasculitisFrance
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)SuspendedANCA Associated VasculitisUnited States
Clinical Trials on mycophenolate mofetil
-
University of GiessenNovartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg UniversityCompletedPolyomavirus InfectionsGermany
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States
-
Nanjing University School of MedicineCompletedNephritis | Henoch-Schoenlein PurpuraChina
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
Nanjing University School of MedicineCompletedVasculitis | Anti-Neutrophil Cytoplasmic AntibodyChina
-
Teva Branded Pharmaceutical Products R&D, Inc.ParexelTerminatedStable Renal Transplant Recipients
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Panacea Biotec LtdCompletedHealthy VolunteersIndia
-
Fred Hutchinson Cancer CenterUniversity of WashingtonCompleted
-
Samsung Medical CenterUnknown